29 results on '"Compernolle, Griet"'
Search Results
2. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label
3. Prediction and Reduction of the Aggregation of Monoclonal Antibodies
4. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center
5. Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease
6. Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease
7. Clinically relevant dosing and pharmacokinetics of DNA-encoded antibody therapeutics in a sheep model
8. Antibodies Toward Vedolizumab Appear from the First Infusion Onward and Disappear Over Time
9. Real-world Endoscopic and Histological Outcomes Are Correlated with Ustekinumab Exposure in Patients with Ulcerative Colitis
10. Mo1559: USTEKINUMAB EXPOSURE AFFECTS REAL-WORLD ENDOSCOPIC AND HISTOLOGIC OUTCOMES IN ULCERATIVE COLITIS
11. Generation and characterization of a unique panel of anti-adalimumab specific antibodies and their application in therapeutic drug monitoring assays
12. Development and validation of immunoassays for monitoring of guselkumab and anti-guselkumab antibodies in patients with moderate-to-severe psoriasis
13. Supplemental material for Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
14. Anti-infliximab antibodies: How to compare old and new data?
15. Evaluating Efficacy, Safety, and Pharmacokinetics After Switching From Infliximab Originator to Biosimilar CT-P13: Experience From a Large Tertiary Referral Center
16. Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease
17. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn’s Disease: A Prospective Multicentre Study
18. Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates
19. Endoscopic remission can be predicted by golimumab concentrations in patients with ulcerative colitis treated with the changed label.
20. Golimumab Trough Levels Predict Mucosal Healing and Success of Dose Optimization: A Prospective Observational Study
21. Recent Anti-TNF Exposure Predicts Lower Vedolizumab Trough Concentrations in Patients with Crohn Disease
22. Antibodies Towards Vedolizumab Appear from Week 2 Onwards and Disappear upon Treatment
23. Anti-Infliximab Antibody Concentrations Guide Therapeutic Decision-Making in Patients with Crohn's Disease Losing Clinical Response
24. Subcutaneous Absorption Contributes to Observed Interindividual Variability in Adalimumab Serum Concentrations in Crohn's Disease: A Prospective Multicentre Study.
25. Bioassay Development for Ultrasensitive Detection of Influenza A Nucleoprotein Using Digital ELISA
26. An Optimized Anti-infliximab Bridging Enzyme-linked Immunosorbent Assay for Harmonization of Anti-infliximab Antibody Titers in Patients with Inflammatory Bowel Diseases
27. Sa1916 - Anti-Infliximab Antibody Concentrations Guide Therapeutic Decision-Making in Patients with Crohn's Disease Losing Clinical Response
28. Sa1883 - Antibodies Towards Vedolizumab Appear from Week 2 Onwards and Disappear upon Treatment
29. Sa1878 - Recent Anti-TNF Exposure Predicts Lower Vedolizumab Trough Concentrations in Patients with Crohn Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.